Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid

Abstract

Abstract Background B cell depleting therapy is widely used for lymphoproliferative diseases and immune-mediated disorders, including mucous membrane pemphigoid. The latter is an autoimmune blistering disease affecting predominantly the mucosae potentially associated with devastating complications. Methods A 71-year-old patient with severe mucous membrane pemphigoid involving ocular, oral pharyngeal and laryngeal involvement is described. To control the disease, the patient was given rituximab therapy in combination with oral corticosteroids. He subsequently experienced an epithelial herpes simplex virus keratitis in one eye and 3 months later in his fellow eye. Topical treatment with ganciclovir resulted in prompt recovery. Results For the first time, a correlation between rituximab and bilateral epithelial herpes simplex virus keratitis is described. Conclusions Although rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of herpes simplex virus keratitis.

Keywords

• Epithelial keratitis
• Herpes simplex virus
• Mucous membrane pemphigoid
• Ocular inflammation
• Rituximab